Along this line, 27 (29%) of MS patients had AMH concentrations below 0.7 ng/ml, of which 17 (60%) were in the 40- to 45-year-old group, four (14.8%) in the 36–40 group, and six (22.2%) were below 35 years old. Here, AMH is linked to myeloid sarcoma.